How Do We Sign up?
· Sign-up instructions and documents for University Research Partners (universities, schools of pharmacy, and other schools) are here.
· Sign up instructions and documents for Strategic Action Partners are here.
· Sign up instructions for Funding Partners are here.
· Sign up instructions for individual Participants (PIs, researchers, graduate students, leaders, experts, innovators and other participants) are here.
What is the Opportunity?
As a University Research Partner, you (and/your PIs and research teams) will be joining with many other researchers, leaders, experts, innovators and students from leading universities, colleges of pharmacy, organizations, associations, foundations, and government agencies from across the US and states, to help address one of the biggest public health challenges in the US – non-optimized use of medications and vaccines (e.g. adverse drug events, non-adherence, misuse, abuse, and other challenges). Recent research by our group has identified potential benefits of addressing this challenge using an all stakeholder, research-driven, ecosystem-level approach.
What Makes this Study Unique?
What makes this study unique is the use of new science (service-dominant logic and service ecosystem design science), new methods (Scalable Transformation Action Research (STAR) and Research Regatta), and advanced collaboration tools and technologies (e.g. Google Workspace, Teams, Zoom), designed to enable many universities, researchers, organizations, associations, foundations and government agencies to work collaboratively – at scale – to address shared challenges in a way that has not, until now, been possible.
What Are the Study Goals?
The study has two goals, represented by two phases of activity.
· Phase 1, Planning (August 2021 – March 2022). In this phase, you and your investigator teams will help facilitate the co-creation of a 10 year ecosystem-level strategic framework and plan and prioritized national research agenda for the entire US medications ecosystem. This will be designed to save millions of lives and as much as $528 Billion per year in likely avoidable spending.
· Phase 2. Implementation (April 2022 – December 2031). University research partners will provide ongoing research and data to help guide action to optimize medications across the ecosystem.
What is the Role of University Research Partners?
University Research Partners will support the first phase of this study by co-leading study sections, helping to engage Strategic Action Partners and Funding Partners, assembling data and conduct analysis of data. Study Sections are special workgroups focused on topics – such as payment/practice transformation, interoperability, access and equity, or state-level transformation. Funding Partners are foundations, philanthropy, government agencies and others who financially support Study Sections. Strategic Action Partners are leaders and experts from leading state and national organizations, associations, foundations, and government agencies interested in medications and vaccines. They contribute both time and collaborative funding to support the planning and implementation processes.
What are the Expected Time Commitments of PIs, Investigators and Students?
During the unfunded “development” phase of the project (tentatively from September 2021 – January 2022), PIs may plan to spend an estimated 10 -15 hours a month, while other supporting researchers spend ~2-4 hours a month. Research office leaders, Deans, Chairs and others may also be invited to provide assistance to engage Strategic Action Partners (e.g. Medicaid, health plans, health systems, physician groups, pharmacies, pharma, etc.) and Funding Partners to provide financial support for the funded phases of the project.
Once collaborative funding is generated, planning grants may be issued to support planning, and analysis of data to generate larger grants. For example, a PI and research team at a School of Pharmacy might get a planning grant of $100,000 - $200,000 for a 6-12 month time period. At this point, time commitments will be based on the grant requirements.
What Are the “Outputs” of the Study?
The first output of the study is an evidence-based ecosystem-level strategic framework and plan and nationally prioritized research agenda for improving the US medications ecosystem for 2022 – 2031. This will include specific plans and research agendas for each study section. The second set of outputs (on the research side) is a series of larger-scale projects to support implementation of the plans from 2022 - 2031.